The deregulation of receptor tyrosine kinases (RTKs) or intracellular tyrosine kinases coupled to RAS activation has been involved in the development of a number of tumors, such as those in breast cancer, ovarian cancer and leukemia. Here, NTRK1 is linked to ovarian carcinoma.